In 2025, Health Canada has recast its methodology for overseeing pharmaceuticals, biologics, and innovative therapies. Through advanced Regulatory Affairs Services, the agency’s shifting framework mirrors a worldwide move toward speedier, science-driven, and technology-enabled review processes. For international pharma and biotech organizations, knowledge of these drug approval routes is key to organizing an effective, compliant, and competitive market penetration of Canada.

Health Canada's modernization is designed to maintain stringent standards of safety and efficacy while facilitating patient access to new treatments more quickly. The increasing harmonization with global regulators such as the FDA and EMA has made Canada one of the most forward-thinking drug regulatory environments in the world.

Therapeutic Products Directorate (TPD) – for pharmaceuticals and medical devices.
Biologics and Genetic Therapies Directorate (BGTD) – for biologics, vaccines, and gene or cell-based treatments.

The two directorates are responsible for assuring that drugs are of safety, efficacy, and quality standards under the Food and Drugs Act and its supporting regulations.

Read the Full blog, to know more :

https://resource.ddregpharma.com/blogs/health-canada-drug-approval-pathways-2025-a-complete-guide-for-global-pharma-companies/

Follow us on :
Facebook: https://www.facebook.com/DDReg/
LinkedIn: https://www.linkedin.com/company/ddregpharma
Twitter: https://x.com/DDRegPharma